The European Consortium for the Study of Topical Treatment of Neovascular Glaucoma– the STRONG Study, is an FP7 funded consortium to assess the efficacy of a topical anti-angiogenic agent in the treatment of Neovascular Glaucoma secondary to ischemic CRVO.
Coordinated by the department of Ophthalmology of the University Eye Hospital in Mainz, Germany, the STRONG Study is a Phase II/III randomised, double-masked, 3-group, placebo-controlled trial to assess the efficacy of Aganirsen antisense oligonucleotide in reducing the rate of iris neovascularisation and NVG development after ischemic CRVO. Aganirsen is an antisense oligonucleotide inhibiting IRS-1 in pro-angiogenic conditions developed by Gene Signal, a research and development based biotechnology company focused on developing drugs for the regulation of angiogenesis.
Strong Study News
The “STRONG” Consortium has been established to study Neovascular Glaucoma secondary to ischemic Central Retinal Vein Occlusion (i-CRVO), a rare eye disease. Aganirsen antisense oligonucleotide topical eye emulsion will be used for “STRONG Study”, the first-ever randomized controlled multicentre study for Neovascular Glaucoma secondary to i-CRVO. The STRONG study will also provide new insights into
Read more »